CNBC's Final Trades: Merck, Intel, Meta Platforms, Goldman Sachs And This Biopharma Stock

On CNBC’s “Halftime Report Final Trades,” Joseph Terranova of Virtus Investment Partners said he was “looking for opportunities in quality names” and cited Merck & Co., Inc MRK as his pick.

Terranova added that he had taken a position in Merck on Friday because of its “6% cash flow yield, very cheap valuation.” He further said, “Its growth portfolio is undervalued. This stock is going a lot higher.”

Rob Sechan of New Edge Capital Group named Intel Corporation INTC, saying that he liked the semiconductor space right now. “We see demand continuing to expand while supply remains tight across nearly every end market,” he added.

Jim Lebenthal of Cerity Partners cited AbbVie Inc ABBV, saying “pharma is coming back right now.” “Plus, if you’re you know a little negative on the markets, like I am, this is a good place to hide out,” he added.

Stephen Weiss of Short Hills Capital Partners named Meta Platforms Inc FB as his pick, while Bryn Talkington of Requisite Capital Management cited Goldman Sachs Group Inc GS as hers.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasMediaTrading IdeasBryn TalkingtonCerity PartnersCNBCJim LebenthalJoseph TerranovaNew Edge Capital GroupRequisite Capital ManagementRob SechanShort Hills Capital PartnersStephen WeissVirtus Investment Partners
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!